
ALLO Stock Forecast & Price Target
ALLO Analyst Ratings
Bulls say
Allogene Therapeutics Inc. demonstrates a promising outlook due to its innovative pipeline, particularly with the potential for cema-cel to achieve a 25-30% improvement in minimal residual disease (MRD) conversion in the upcoming futility analysis, which could significantly enhance stock valuation. Additionally, the company has a robust financial position with $258 million in cash, providing a runway until the first quarter of 2028, which enables continued development of its core programs in cancer and autoimmune diseases. Recent analyses, such as the ZUMA-7 study, underscore the increasing relevance of MRD negativity in improving event-free survival, indicating that successful outcomes in ongoing trials could yield substantial benefits for the company's future performance.
Bears say
Allogene Therapeutics Inc faces significant risks stemming from potential failures in its clinical trials, particularly with key products like UCART19, which could negatively affect investor confidence across its entire platform. The company is also confronting considerable competition in the immuno-oncology landscape, which may dilute market share for its therapies. Additionally, persistent net losses, as evidenced by a $38.8 million loss in the latest quarter, underscore the financial instability, while challenges related to manufacturing quality control may hinder product launch timelines and operational scalability.
This aggregate rating is based on analysts' research of Allogene Therapeutics Inc and is not a guaranteed prediction by Public.com or investment advice.
ALLO Analyst Forecast & Price Prediction
Start investing in ALLO
Order type
Buy in
Order amount
Est. shares
0 shares